0
Crinetics Pharmaceuticals, Inc. Banner Image

Crinetics Pharmaceuticals, Inc. has reached its limit for free report views

Work for Crinetics Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Crinetics Pharmaceuticals, Inc.

  • Ticker CRNX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Crinetics Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in San Diego, California
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinicalMore trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing an oral nonpeptide somatostatin receptor type 5 (sst5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.
Crinetics Pharmaceuticals, Inc.

Most Recent Annual Report

Crinetics Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Crinetics Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports